secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000939767-22-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M
-------------------------------------------------------------------------

- Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.
- GAAP net income $68.6M ($0.21 diluted EPS) vs $1.6M ($0.00); non-GAAP EPS $0.26 vs $0.09.
- Cabozantinib franchise growth: increased demand for CABOMETYX+OPDIVO in first-line RCC and DTC label expansion.
- Cash and investments $2.0B at March 31, 2022, up from $1.9B at December 31, 2021.
- Pipeline advancing: XL092 phase 3 STELLAR-303 to initiate Q2 2022; phase 1 trials of XL092, XB002, XL102 ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/0000939767-22-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/exel-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer